In 2023, the FDA approved sulbactam-durlobactam, a newer β-lactam/beta-lactamase inhibitor combo, for treating hospital-acquired and ventilator-associated pneumonia caused by carbapenem-resistant strains of Acinetobacter baumannii [16]. The gene discussed is LACTB; the disease is ventilator-associated pneumonia.